Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.

Animals Cell Line, Tumor Cell Transformation, Neoplastic Chemistry Techniques, Synthetic Glutamate Carboxypeptidase II / metabolism Hydrophobic and Hydrophilic Interactions Isotope Labeling Male Mice Microscopy, Fluorescence Nuclear Medicine Oligopeptides / chemical synthesis Optical Imaging / methods Prostatic Neoplasms / diagnostic imaging Radioactive Tracers Surgery, Computer-Assisted Tissue Distribution
PSMA fluorescence hybrid tracer intraoperative guidance prostate cancer

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
01 2019
Historique:
received: 11 04 2018
accepted: 27 07 2018
pubmed: 22 9 2018
medline: 5 11 2019
entrez: 22 9 2018
Statut: ppublish

Résumé

The prostate-specific membrane antigen (PSMA)-targeted radiotracers

Identifiants

DOI: 10.2967/jnumed.118.212720 PMID: 30237214 PMC: PMC6354225
pubmed: 30237214
pii: jnumed.118.212720
doi: 10.2967/jnumed.118.212720
pmc: PMC6354225
doi:

Substances chimiques

Oligopeptides 0
Radioactive Tracers 0
Glutamate Carboxypeptidase II EC 3.4.17.21

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-78

Informations de copyright

© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Mol Imaging Biol. 2014 Dec;16(6):747-55
pubmed: 24849133
J Nucl Med. 2014 Jun;55(6):995-1001
pubmed: 24700882
Am J Nucl Med Mol Imaging. 2017 Jul 15;7(3):138-147
pubmed: 28721307
Mamm Genome. 2001 Feb;12(2):117-23
pubmed: 11210180
World J Urol. 2018 Apr;36(4):603-608
pubmed: 29372353
J Nucl Med. 2018 Apr;59(4):639-645
pubmed: 29191856
Cancer Biother Radiopharm. 2017 Mar;32(2):67-73
pubmed: 28301262
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
J Nucl Med. 2015 Aug;56(8):1169-76
pubmed: 26089548
Ann Nucl Med. 2017 Nov;31(9):696-702
pubmed: 28831739
Clin Genitourin Cancer. 2016 Oct;14(5):e549-e552
pubmed: 27318956
J Nucl Med. 2018 Jun;59(6):986-992
pubmed: 29449447
Chem Commun (Camb). 2017 Feb 4;53(10):1611-1614
pubmed: 28085163
EJNMMI Res. 2015 Dec;5(1):68
pubmed: 26608882
Mol Cancer Ther. 2014 Nov;13(11):2595-606
pubmed: 25239933
Theranostics. 2017 Jun 11;7(9):2350-2362
pubmed: 28744319
J Nucl Med. 2018 Sep;59(9):1406-1411
pubmed: 29371407
Curr Med Chem. 2012;19(9):1316-22
pubmed: 22304710
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1278-87
pubmed: 26768422
Bioconjug Chem. 2012 Dec 19;23(12):2377-85
pubmed: 23157641
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20
pubmed: 12677301
Clin Transl Imaging. 2017;5(4):323-341
pubmed: 28804703
J Nucl Med. 2012 Jul;53(7):1034-40
pubmed: 22645297
Methods. 2017 Nov 1;130:42-50
pubmed: 28666778
Chemistry. 2011 Dec 23;17(52):14718-22
pubmed: 22147338
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100
pubmed: 28255795
BJU Int. 2017 Jul;120(1):40-47
pubmed: 27862863
Nat Med. 2015 Aug;21(8):955-61
pubmed: 26168295
Mol Pharm. 2018 Mar 5;15(3):934-946
pubmed: 29400475
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495
pubmed: 29282518
J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S
pubmed: 28864615
J Med Imaging Radiat Oncol. 2017 Dec;61(6):732-738
pubmed: 28623872
J Pharm Sci. 2003 Nov;92(11):2236-48
pubmed: 14603509
J Med Chem. 2010 Jul 22;53(14):5333-41
pubmed: 20568777
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Theranostics. 2015 Oct 18;5(12):1388-401
pubmed: 26681984
Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70
pubmed: 21861274
Clin Cancer Res. 2015 Feb 15;21(4):771-80
pubmed: 25501577
Urologe A. 2017 Jan;56(1):32-39
pubmed: 27885457
J Nucl Med. 2017 Feb;58(2):235-242
pubmed: 27635024
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Clin Cancer Res. 2016 Mar 15;22(6):1304-6
pubmed: 26712691
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):623-32
pubmed: 21170526
EJNMMI Res. 2014 Dec;4(1):63
pubmed: 26116124
J Nucl Med. 2015 Jun;56(6):914-20
pubmed: 25883127

Auteurs

Margret Schottelius (M)

Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany m.schottelius@tum.de.

Alexander Wurzer (A)

Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany.

Katharina Wissmiller (K)

Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany.

Roswitha Beck (R)

Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany.

Maximilian Koch (M)

Chair for Biological Imaging (CBI), Technische Universität München, Munich, Germany, and Institute for Biological and Medical Imaging (IBMI), Helmholtz Centre Munich, Oberschleißheim, Germany.

Dimitrios Gorpas (D)

Chair for Biological Imaging (CBI), Technische Universität München, Munich, Germany, and Institute for Biological and Medical Imaging (IBMI), Helmholtz Centre Munich, Oberschleißheim, Germany.

Johannes Notni (J)

Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany.

Tessa Buckle (T)

Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.

Matthias N van Oosterom (MN)

Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.

Katja Steiger (K)

Institute for Pathology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; and.

Vasilis Ntziachristos (V)

Chair for Biological Imaging (CBI), Technische Universität München, Munich, Germany, and Institute for Biological and Medical Imaging (IBMI), Helmholtz Centre Munich, Oberschleißheim, Germany.

Markus Schwaiger (M)

Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.

Fijs W B van Leeuwen (FWB)

Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.

Hans-Jürgen Wester (HJ)

Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › Transformation cellulaire néoplasique › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Technologie pharmaceutique › Techniques de chimie synthétique › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Metalloproteases › Metalloexopeptidases › Glutamate carboxypeptidase II › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Phénomènes chimiques › Interactions hydrophobes et hydrophiles › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Techniques d'investigation › Marquage isotopique › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Techniques d'investigation › Microscopie de fluorescence › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Professions de santé › Médecine › Radiologie › Médecine nucléaire › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Techniques d'investigation › Imagerie optique › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Traceurs radioactifs › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Procédures de chirurgie opératoire › Chirurgie assistée par ordinateur › Synthesis and Preclinical Characterization of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Synthesis and Preclinical Characterization of...